Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

Evoq Remedies Ltd - 543500 - Announcement under Regulation 30 (LODR)-Resignation of Director

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, we hereby inform you that Mr. Tarunkumar Patel (DIN: 09433349) has resigned as a Non-Executive Director of the Company with effect from 25th May, 2023. Further, the Company has received confirmation from Mr. Tarunkumar Patel (DIN: 09433349) that there is no other material reason for his resignation other than those which are provided in the resignation letter.
25-05-2023
Bigul

Evoq Remedies Ltd - 543500 - Submission Of Audited Financial Results For The Half Year And Financial Year Ended On 31St March, 2023 Along With Auditor'S Report And Declaration

 In reference to captioned subject and pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are hereby submitting the Audited Financial Results for the Half Year and Financial Year ended on 31st March, 2023 along with Auditor's Report and Declaration.
25-05-2023
Bigul

Evoq Remedies Ltd - 543500 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. 25Th May, 2023

 Pursuant to second proviso to Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e. 25th May, 2023, at the Registered Office of the Company which commenced at 3:00 P.M. and concluded at 6:35 P.M. inter-alia has considered and approved: 1. Audited Financial Results for the Half Year and Financial Year ended on 31st March, 2023 along with Auditor's Report and Declaration. 2. Appointment of Mr. Dahyabhai Patel (DIN: 07061899) as a Managing Director of the Company w.e.f. 25th May, 2023, subject to approval of the Shareholders in the General Meeting. 3. Resignation of Mr. Tarunkumar Patel (DIN: 09433349) as a Director of the Company w.e.f. 25th May, 2023.
25-05-2023
Bigul

Evoq Remedies Ltd - 543500 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held On 25Th May, 2023

 Evoq Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 ,inter alia, to consider and approve We hereby inform you that a meeting of the Board of Directors of the Company will be held on Thursday, 25th May, 2023 at 3:00 P.M. at the Registered Office of the Company situated at A-1106, Empire Business Hub, Near AUDA Water Tank, Science City Road, Sola, Ahmedabad 380060, inter alia, to consider and approve the Audited Financial Results of the Company for the Half Year and Year ended on 31st March, 2023 along with Auditor's Report. Pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 read with SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Circular No. LIST/COMP/01/2019-20 dated 2nd April, 2019 issued by BSE, the Trading Window has been closed with effect from 1st April, 2023 and shall continue to remain closed till 48 hours after the announcement of the financial results on 25th May, 2023.
10-05-2023
Bigul

Evoq Remedies Ltd - 543500 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyEvoq Remedies Ltd 2CIN NO.U24230GJ2010PLC059692 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 9.58 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Parth Kamdar Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Payal Bhumishth Patel Designation: Chief Financial Officer EmailId: [email protected] Date: 28/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
28-04-2023
Bigul

Evoq Remedies Ltd - 543500 - Subject: Submission Of Certificate Under Regulation 40(9) Read With Regulation 40(10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended On 31St March, 2023

 With reference to the captioned subject, kindly find attached herewith Certificate issued under Regulation 40(9) read with Regulation 40(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the financial year ended on 31st March, 2023.
21-04-2023
Bigul

Evoq Remedies Ltd - 543500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 With reference to the captioned subject, we hereby submit the confirmation Certificate received from M/s. Accurate Securities & Registry Private Limited, Registrar and Share Transfer Agent (RTA) as per Regulation 74(5) of the Securities and Exchange Board India (Depository and Participant) Regulations, 2018 for the Quarter ended on 31st March, 2023.
11-04-2023
Bigul

Evoq Remedies Ltd - 543500 - Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Financial Year Ended On 31St March, 2023

 With reference to the captioned subject, kindly find attached herewith Certificate issued under Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 for the financial year ended on 31st March, 2023.
11-04-2023
Bigul

Evoq Remedies Ltd - 543500 - Announcement under Regulation 30 (LODR)-Resignation of Chairman and Managing Director

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para a of Part a of Schedule III to the said Regulations, we hereby inform you that Mr. Bhumishth Patel has resigned from the position of the Managing Director of the Company with effect from 31st March, 2023. Further, the Company has received confirmation from Mr. Bhumishth Patel that there are no other material reasons for his resignation other than those which are provided in the resignation letter.
31-03-2023
Bigul

Evoq Remedies Ltd - 543500 - Closure of Trading Window

 Pursuant to Clause 4 of Schedule B of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time and Company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities, this is to inform that the trading window for dealing in Equity Shares of the Company by the Insiders will be closed from Saturday, 1st April, 2023 till 48 hours after the declaration and publication of Audited Financial Results for the for the Quarter and Year ended on 31st March, 2023.
31-03-2023
Next Page
Close

Let's Open Free Demat Account